Featured Products

LGM Pharma is proud to present to you our newest Prostaglandin products.

A prostaglandin is any member of a group of lipid compounds that are derived enzymatically from fatty acids and have important functions in the animal body.

Currently LGM Pharma supplies the following products, available for your R&D purposes:

Latest News

LGM Pharma Moves Corporate Headquarters to New Location

LGM Pharma, a leading supplier of active pharmaceutical ingredients to various global pharmaceutical firms, announced its recent move into a new corporate headquarters in Boca Raton, Florida. The move is part of the firm's long-term plan for steady and careful growth, meeting both their current needs as well as accommodating future development.

The company also paid careful consideration to ways that would improve the at-work experience for their employees, allowing them to be more efficient and productive, through space planning and collaborative workspaces.

"Our new corporate headquarters will offer LGM Pharma the flexibility that we need as we expand as a company. This move represents the company we are establishing," said Mendy Schurder, COO of LGM Pharma.

The company's new address is 6400 Congress Avenue, Suite 1400, Boca Raton, Florida 33487.

Disclaimer: Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Recent Blog Posts

Advent of combo therapy increases the chances of complete cancer remission with Temsirolimus at its forefront Posted on: 6/21/11 Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API's), such as Temsirolimus CAS# 162635-04-3... More > Everolimus shoots two very different birds with one stone; cancer cells and coronary stents Posted on: 6/8/11 As a kinase inhibitor, Everolimus effectively inhibits cancer cells from dividing. Since then, the use of Everolimus has extended to treatment of subependymal giant cell astrocytoma, pancreatic neuroendocrine tumors and other neoplasms. It has also gained acceptance as an orally administered drug to prevent transplant rejection. Evidence for this indication has been presented by Dr. Ron Shapiro wherein high-dose Everolimus improved graft survival in renal transplantation... More > Toremifene on the fast track of joining other anti-androgen agents in the prevention and treatment of prostate cancer Posted on: 6/3/11 Although not brand new, Toremifene has been found to be as effective as Tamoxifen, in breast cancer, as a selective estrogen receptor modulator (SERM) with the added advantage of better patient tolerability and lesser adverse effects. Several drugs for this specific type of cancer have been developed but only a handful has made it to the market. In this present era, the internet has become a center for gathering information. Information about anti-breast cancer drugs is readily available with just one click. Questions regarding the effectiveness and safety profile of a particular anti-cancer drug, particularly for breast cancer, have been answered albeit somewhat lacking and needing further research on long term safety profiles... More >